Highlights

Osteopore gains regulatory approval in Switzerland under EU Medical Device Regulation (MDR).

Approval covers full product portfolio of off-the-shelf and custom-made implants.

OSX shares soared 80% to 1.8 cents on 14 July 2025 following the announcement.

Osteopore Limited (ASX:OSX), a regenerative medicine company specialising in 3D-printed, bioresorbable implants, announced on 14 July 2025 that it has secured market approval for its products in Switzerland under the European Union’s Medical Device Regulation (MDR). The milestone triggered a sharp rise in investor confidence, sending Osteopore shares up by 80% to 1.8 cents per share.

The approval covers Osteopore’s complete portfolio, including both off-the-shelf and custom-made implants, improving the company’s capacity to support market entry into Switzerland and across the broader European region. The clearance is a culmination of Osteopore’s strategic efforts, including a successful transition to MDR compliance in 2023, followed by a key partnership with Zimmer Biomet (NYSE and SIX:ZBH) in 2024.

Switzerland, although not an EU member, participates in the single market through bilateral agreements. Following the EU's introduction of the new MDR framework in May 2021, Switzerland implemented its own regulations in the absence of an updated Mutual Recognition Agreement. As a result, medical device companies now require specific Swiss approvals, even if their products are CE-marked under MDR.

Osteopore’s ability to meet these requirements has positioned it to tap into a valuable segment of the European medical device market. In particular, its custom-made implants for neurosurgery and orthopaedic surgery—previously approved in the EU—are now cleared for the Swiss market, enabling Zimmer Biomet to distribute a comprehensive suite of Osteopore’s craniofacial products throughout the region.

The partnership with Zimmer Biomet extends across multiple geographies, including Europe, the Middle East and Africa (EMEA), Asia Pacific (APAC), and Australia and New Zealand. This collaboration leverages Zimmer Biomet’s established distribution channels and reinforces Osteopore’s strategy of global expansion through strategic alliances.

According to market forecasts, the European cranial implant market is projected to reach USD 527.6 million by 2027, with custom-made implants representing the largest segment. Osteopore's products are designed to support natural bone regeneration and gradually dissolve in the body, offering a regenerative alternative to traditional permanent implants.

CEO Dr Yujing Lim said the approval marks a significant step forward in Osteopore’s commercial roadmap: “We are delighted to be in the position to support a coordinated approach to the European market, specifically Switzerland, with Zimmer Biomet.”